Research programme: mRNA-based cancer vaccine - Immatics N.V./Moderna Therapeutics
Latest Information Update: 22 Sep 2023
At a glance
- Originator Immatics N.V.; Moderna Therapeutics
- Class Antineoplastics; Cancer vaccines; Immunotherapies; RNA vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Research Cancer